Fisher & Paykel Healthcare Corporation Limited announced today it has appointed Mark Cross to the Board as a non-executive director with effect from 1 October 2024. The addition of Mr Cross will fill the vacancy on the Board upon Scott St John’s retirement at the end of August.
Mr St John, current Chair of Fisher & Paykel Healthcare, said, “Mark is a strategic thinker who understands the technology and innovation sector and brings a fresh perspective. With strong business acumen and a background in global finance, his skills will complement those of the other directors. We welcome him to the Board and look forward to getting his insights.”
Mr Cross has extensive governance experience in other listed companies. He currently chairs the board of Chorus, where he has been a director since 2016. He is also a director of Xero, and a board member and Investment Committee Chair of Accident Compensation Corporation (ACC). He is a former chair of Milford Asset Management and a former director of Z Energy, Genesis Energy and Argosy Property.
Previously, Mr Cross held executive positions with Deutsche Bank in London and Sydney, as well as Lloyds Corporate Finance/Southpac Corporation in Australia and New Zealand. In those roles, he was an advisor to businesses across a range of sectors including healthcare, utilities, energy, industrials and chemicals.
Mr Cross is a member of Chartered Accountants Australia and New Zealand, a chartered fellow of the New Zealand Institute of Directors and a member of the Australian Institute of Company Directors. He resides in New Zealand.
The Fisher & Paykel Healthcare Board has determined that Mr Cross will be an independent director. He will chair the Audit and Risk Committee.
Scott St John will retire from the Board of Fisher & Paykel Healthcare from the close of the company’s annual shareholders’ meeting on 28 August. The Board has elected current director Neville Mitchell to succeed Mr St John as Chair.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Contacts:
Authorised by Fisher & Paykel Healthcare Corporation Limited’s Board of Directors.